Formulation composition of botulinum toxins in clinical use

Journal of Drugs in Dermatology

Volumn 9, Issue 9, 2010, Pages 1085-1091

  Pickett, Andy ^a   Perrow, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BOTULINUM TOXIN; DEXTRAN; EMULSIFYING AGENT; GELATIN; HUMAN SERUM ALBUMIN; PRESERVATIVE; SODIUM; SOLVENT; SUCROSE; WETTING AGENT; EXCIPIENT;

DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LETHAL DOSE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; CHEMISTRY; DRUG PACKAGING; SOLUTION AND SOLUBILITY;

BOTULINUM TOXINS; CHEMISTRY, PHARMACEUTICAL; DRUG PACKAGING; EXCIPIENTS; PHARMACEUTICAL SOLUTIONS;

EID: 77957938935     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther.1982;19:165- 194. (Pubitemid 13112836)
2. Poulain B, Popoff M, Molgo J. How do the botulinum neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action. Botulinum J. 2008;1:14-87.
3. Cordivari C, Misra VP, Catania S, et al. New therapeutic indications for botulinum toxins. Mov Disord. 2004;19 Suppl 8:S157-S161. (Pubitemid 38967526)
4. Grumelli C, Verderio C, Pozzi D, et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology. 2005;26:761-767. (Pubitemid 41427515)
5. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:Suppl 2:R20.
6. Eisele KH, Taylor HV. Dissociation of the 900 kDa neurotoxin complex from C.botulinum under physiological conditions. Toxicon. 2008;51:Suppl 1:P10.
7. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40:374-380.
8. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584:1595.
9. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312:592-596.
10. Rummel A, Mahrhold S, Bigalke H, et al. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol. 2004;51:631-643. (Pubitemid 38233933)
11. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol. 2003;10:13-18. (Pubitemid 36034171)
12. Fernandez-Salas E, Steward LE, Ho H, et al. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A. 2004;101:3208-3213. (Pubitemid 38327759)
13. Brunger AT, Breidenbach MA, Jin R, et al. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 2007;3:1191-1194. (Pubitemid 47510272)
14. Schiavo G, Rossetto O, Catsicas S, et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem. 1993;268:23784-23787. (Pubitemid 23335346)
15. Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature. 2004;432:925-929. (Pubitemid 40037157)
16. Chen S, Kim JJ, Barbieri JT. Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem. 2007;282:9621-9627. (Pubitemid 47104595)
17. Frevert J. Xeomin is free from complexing proteins. Toxicon. 2009;54:697-701.
18. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol. 2009;32:28-31.
19. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA. 2001;285:1059-1070. (Pubitemid 32176420)
20. Panjwani N, O'Keeffe R, Pickett AM. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1:153-166.
21. Panjwani N, Pickett A, O'Keeffe R. Botulinum type A toxins in clinical use: a comparison of specific potency and protein content. Neurotoxicity Res. 2006;9:2-3:225-254:P47.
22. Wohlfarth K, Sycha T, Ranoux D, et al. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: Time for a reassessment? Curr Med Res Opin. 2009;25:1573-1584.
23. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80-99.
24. Roy S, Henderson I, Nayar R, et al. Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations. J Pharm Sci. 2008;97:5132-5146.
25. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther. 2007;32:387-402. (Pubitemid 47063164)
26. Pickett A, Caird D. Comparison of type a botulinum toxin products in clinical use. J Clin Pharm Ther. 2008;33:327-328. (Pubitemid 351629749)
27. Tumber PS, Louis I. Botulinum toxin type a therapy and human serum albumin. Anesthesiology. 2006;104:1108-1109.
28. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin - Serious adverse events reported worldwide in 1998-2000. Br J An-aesth. 2003;91:625-630. (Pubitemid 37369521)
29. Cetnarowski W, Dadas C. Botulinum toxin type A therapy and human serum albumin. Anesthesiology. 2006;104:1108-1109.
30. Pickett A, Rzany B. Botulinum toxin in aesthetic applications: "How often misused words generate misleading thoughts." J Cosmet Laser Ther. 2009;1-2.
31. Rystedt A, Swartling C, Naver H. Anhidrotic effect of intradermal injections of botulinum toxin: A comparison of different products and concentrations. Acta Derm Venereol. 2008;88:229-233. (Pubitemid 351743864)
32. Panicker JN, Muthane UB. Botulinum toxins: Pharmacology and its current therapeutic evidence for use. Neurol India. 2003;51:455-460. (Pubitemid 38195909)
33. Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009;61:149-150.
34. Akers MJ. Excipient-drug interactions in parenteral formulations. J Pharm Sci. 2002;91:2283-2300. (Pubitemid 35231192)
35. U.S. Food and Drug Administration. The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use Available at: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm125182.htm. Accessed December 2009.
36. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. Biologicals. 2003;31:245-249. (Pubitemid 37414919)
37. Sakaguchi M, Inouye S. Systemic allergic reactions to gelatin included in vaccines as a stabilizer. Jpn J Infect Dis. 2000;53:189-195. (Pubitemid 32140741)
38. Kelso JM. The gelatin story. J Allergy Clin Immunol. 1999;103:200-202.
39. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003;18:1257-1259. (Pubitemid 36826943)
40. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251 Suppl 2:II4-II9.
41. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology. 2003;61:S11-S12. (Pubitemid 37386112)
42. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21 Suppl 5:v9-12.
43. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-15.
44. Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;34:4:213-218.
45. Mohammadi B, Kollewe K, Wegener M, et al. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm. 2009;116:437-441.
46. Moy R, Maas C, Monheit G, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77-83.
47. Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treat-ment of glabellar lines: Interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61:3:421-425.
48. Jones T. Allergan are spending $30m to remove HSA from Botox and replace with rHA. PharmaNet Symposium, London. 2007.
49. Osterberg T, Fatouros A, Mikaelsson M. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ. Pharm Res. 1997;14:892-898. (Pubitemid 27326984)